Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer

HER2-overexpression in tumor tissue is observed in 6 to 23% of advanced gastric cancer (GC) cases, and trastuzumab is an active molecular drug for these patients. There are no data available on whether serum levels of ligands are associated with the response and resistance to trastuzumab in HER2-pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Naoki, Furuta, Koh, Taniguchi, Hirokazu, Sasaki, Yusuke, Shoji, Hirokazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Hamaguchi, Tetsuya, Shimada, Yasuhiro, Yamada, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826254/
https://www.ncbi.nlm.nih.gov/pubmed/26716644
http://dx.doi.org/10.18632/oncotarget.6753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826254/
https://www.ncbi.nlm.nih.gov/pubmed/26716644
http://dx.doi.org/10.18632/oncotarget.6753

Ejemplares similares